Funder
Haematology Society of Australia and New Zealand
Fred Hutchinson Cancer Research Center
Bristol-Myers Squibb
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology,General Medicine,Biotechnology
Reference185 articles.
1. National Cancer Institute—Surveillance Epidemiology and End Results (SEER) Program. Cancer stat facts: leukemia—acute myeloid leukemia (AML). National Institutes of Health Bethesda, MD. 2019. https://seer.cancer.gov/statfacts/html/amyl.html. Accessed 5 Aug 2019.
2. Koenig K, Mims A, Levis MJ, Horowitz MM. The changing landscape of treatment in acute myeloid leukemia. Am Soc Clin Oncol Educ Book. 2020;40:1–12. https://doi.org/10.1200/edbk_279129.
3. DiNardo CD, Wei AH. How I treat acute myeloid leukemia in the era of new drugs. Blood. 2020;135(2):85–96. https://doi.org/10.1182/blood.2019001239.
4. Koenig K, Mims A. Relapsed or primary refractory AML: moving past MEC and FLAG-ida. Curr Opin Hematol. 2020;27(2):108–14. https://doi.org/10.1097/moh.0000000000000561.
5. Choe S, Wang H, DiNardo CD, Stein EM, de Botton S, Roboz GJ, et al. Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML. Blood Adv. 2020;4(9):1894–905. https://doi.org/10.1182/bloodadvances.2020001503.
Cited by
28 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献